Diarrhea News and Research

Latest Diarrhea News and Research

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Nearly 60,000 newly acquired infections per year in Germany's intensive care units

Infections are among the most frequent complications of a stay in hospital and raise the complication and mortality rates. Calculations based on data from the Hospital Infection Surveillance System (Krankenhaus-Infektions-Surveillance-System, KISS) showed an incidence of almost 60 000 newly acquired infections per year in intensive care units in Germany.

25 Feb 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

Researchers from Spain have identified a strain of probiotic bacteria that may be useful in treating ulcers caused by Helicobacter pylori. They report their findings in the February 2011 issue of the journal Applied and Environmental Microbiology.

25 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

FDA allows marketing of Ridascreen Norovirus 3rd Generation EIA assay in the US

The U.S. Food and Drug Administration allowed marketing of the first test for the preliminary identification of norovirus.

24 Feb 2011

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Tranzyme Pharma and Norgine B.V., have initiated dosing of ulimorelin in the first of two, Phase 3 pivotal studies - ULISES. Ulimorelin is Tranzyme's intravenous promotility agent in development for the management of postoperative ileus in hospital and acute care settings.

23 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

Bangladesh cholera vaccine trial

Bangladesh will conduct the world’s largest clinical trial of an affordable cholera vaccine which could save tens of thousands of lives. The study began Thursday and involves nearly 250,000 people near the capital, Dhaka.

20 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

China-Biotics applies 5 new patents for probiotics supplement, preparation

China-Biotics, Inc., the leading developer, manufacturer and distributor of probiotics products in China, today announced it has applied for 5 new patents through its wholly owned subsidiary Growing Bioengineering to the State Bureau of Intellectual Property.

18 Feb 2011

Astellas' Protopic receives Health Canada approval for prevention of eczema flares

Astellas Pharma Canada, Inc. has announced that it has received approval from Health Canada for a new indication for its topical eczema therapy, Protopic® (tacrolimus ointment 0.03% and 0.1%). The new indication means that tacrolimus ointment can be prescribed for maintenance therapy to prevent flares and prolong flare free intervals in patients with moderate to severe atopic dermatitis (commonly called eczema).

17 Feb 2011

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Bioniche presentation focuses on implementing E. coli cattle vaccine to reduce risk of human infection

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, gave a presentation about its E. coli O157 cattle vaccine at the First International One Health Congress in Melbourne, Victoria, Australia.

16 Feb 2011

Also in global health news: Gates Foundation global health head to step down; drug, medical supply shortages in Gaza; food security in N. Korea

Tachi Yamada, president of the global health program at the Bill & Melinda Gates Foundation, on Monday announced he would step down in June after five years serving in the position, the Associated Press/Seattle Post-Intelligencer reports.

16 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Nearly 60,000 newly acquired infections per year in Germany's intensive care units

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

FDA allows marketing of Ridascreen Norovirus 3rd Generation EIA assay in the US

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Forest Labs enters definitive merger agreement to acquire Clinical Data

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Bangladesh cholera vaccine trial

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

China-Biotics applies 5 new patents for probiotics supplement, preparation

Astellas' Protopic receives Health Canada approval for prevention of eczema flares

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Astellas, AVEO enter development, commercialization agreement for tivozanib

Bioniche presentation focuses on implementing E. coli cattle vaccine to reduce risk of human infection

Also in global health news: Gates Foundation global health head to step down; drug, medical supply shortages in Gaza; food security in N. Korea

State court jury rules in favor of Merck in FOSAMAX trial

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in